Magenta Therapeutics Launches Proposed Initial Public Offering
J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
The proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from:
- J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204
- Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectusemail@example.com
- Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, telephone: 631-274-2806.
A registration statement, including a prospectus which is preliminary and subject to completion, relating to these securities and describing the terms of the proposed offering has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The registration statement may be obtained free of charge at the SEC’s website at www.sec.gov under “Magenta Therapeutics, Inc.” This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state or jurisdiction.
About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases.
This press release may contain forward-looking statements, including statements regarding Magenta’s financing plans and planned offering of common stock. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current beliefs, expectations and assumptions regarding the future of Magenta’s business, future plans and strategies, development plans, clinical results and other future conditions. Such statements are subject to certain risks and uncertainties, including, but are not limited to: uncertainties related to the initiation and conduct of trials and studies and other development requirements for Magenta’s product candidates; the risk that any one or more of Magenta’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will be predictive of future results in connection with future studies or trials; risks related to Magenta’s ability to protect and maintain its intellectual property position; and risks related to Magenta’s relationships with third parties. Although Magenta's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Magenta's programs and operations are described in additional detail in its registration statement on Form S-1, which is on file with the SEC. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Manisha Pai, 857-242-1155
Vice President, Communications & Investor Relations
Source: Magenta Therapeutics